{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:36:40Z","timestamp":1792737400653,"version":"4.5.0"},"reference-count":177,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T00:00:00Z","timestamp":1350604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum neurotoxins (BoNTs) cause flaccid paralysis by interfering with vesicle fusion and neurotransmitter release in the neuronal cells. BoNTs are the most widely used therapeutic proteins. BoNT\/A was approved by the U.S. FDA to treat strabismus, blepharospam, and hemificial spasm as early as 1989 and then for treatment of cervical dystonia, glabellar facial lines, axillary hyperhidrosis, chronic migraine and for cosmetic use. Due to its high efficacy, longevity of action and satisfactory safety profile, it has been used empirically in a variety of ophthalmological, gastrointestinal, urological, orthopedic, dermatological, secretory, and painful disorders. Currently available BoNT therapies are limited to neuronal indications with the requirement of periodic injections resulting in immune-resistance for some indications. Recent understanding of the structure-function relationship of BoNTs prompted the engineering of novel BoNTs to extend therapeutic interventions in non-neuronal systems and to overcome the immune-resistance issue. Much research still needs to be done to improve and extend the medical uses of BoNTs.<\/jats:p>","DOI":"10.3390\/toxins4100913","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T05:32:03Z","timestamp":1350883923000},"page":"913-939","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments"],"prefix":"10.3390","volume":"4","author":[{"given":"Sheng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/(SICI)1097-4598(199806)21:6<701::AID-MUS1>3.0.CO;2-B","article-title":"Clinical spectrum of botulism","volume":"21","author":"Cherington","year":"1998","journal-title":"Muscle Nerve"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","article-title":"Botulism: Cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities","volume":"1","author":"Dembek","year":"2007","journal-title":"Disaster Med. Public Health Prep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1749-6632.1994.tb26614.x","article-title":"Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus","volume":"710","author":"Schiavo","year":"1994","journal-title":"Ann. N. Y.Acad. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2958.1994.tb00396.x","article-title":"Mechanism of action of tetanus and botulinum neurotoxins","volume":"13","author":"Montecucco","year":"1994","journal-title":"Mol. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0168-6054(03)00114-4","article-title":"Mode of action of botulinum neurotoxin: Pathological, cellular and molecular aspect","volume":"46","author":"Poulain","year":"2003","journal-title":"Ann. Readapt Med. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.tins.2005.06.001","article-title":"Beyond BOTOX: Advantages and limitations of individual botulinum neurotoxins","volume":"28","author":"Davletov","year":"2005","journal-title":"Trends Neurosci"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583505004051","article-title":"Structure and function of SNARE and SNARE-interacting proteins","volume":"38","author":"Brunger","year":"2005","journal-title":"Q. Rev. Biophys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/toxins3010063","article-title":"Towards new uses of botulinum toxin as a novel therapeutic tool","volume":"3","author":"Pickett","year":"2011","journal-title":"Toxins"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1523\/JNEUROSCI.22-16-06876.2002","article-title":"Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function","volume":"22","author":"Bullens","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbadis.2005.04.005","article-title":"Different response of the knockout mice lacking b-series gangliosides against botulinum and tetanus toxins","volume":"1741","author":"Kitamura","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0609713104","article-title":"Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept","volume":"104","author":"Rummel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35164","DOI":"10.1074\/jbc.M507596200","article-title":"Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins","volume":"280","author":"Tsukamoto","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0041-0101(89)90097-4","article-title":"Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells","volume":"27","author":"Marxen","year":"1989","journal-title":"Toxicon"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0041-0101(91)90102-W","article-title":"The translocation of botulinum A neurotoxin by chromaffin cells is promoted in low ionic strength solution and is insensitive to trypsin","volume":"29","author":"Marxen","year":"1991","journal-title":"Toxicon"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/mpat.1998.0214","article-title":"Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins","volume":"25","author":"Kozaki","year":"1998","journal-title":"Microb. Pathog."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1083\/jcb.200305098","article-title":"Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells","volume":"162","author":"Dong","year":"2003","journal-title":"J. Cell. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1016\/S0021-9258(17)34087-5","article-title":"Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes","volume":"269","author":"Nishiki","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1083\/jcb.200707184","article-title":"Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons","volume":"179","author":"Dong","year":"2007","journal-title":"J. Cell. Biol."},{"key":"ref_19","first-page":"3233","article-title":"Botulinum neurotoxin D-C uses synaptotagmin I\/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxins","volume":"125","author":"Peng","year":"2012","journal-title":"J. Cell. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1091\/mbc.e08-07-0765","article-title":"Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons","volume":"19","author":"Dong","year":"2008","journal-title":"Mol. Biol Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1021\/bi9002138","article-title":"Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F","volume":"48","author":"Fu","year":"2009","journal-title":"Biochemistry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1002008","DOI":"10.1371\/journal.ppat.1002008","article-title":"Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors","volume":"7","author":"Peng","year":"2011","journal-title":"PLoS Pathog."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.toxicon.2008.12.027","article-title":"Receptor and substrate interactions of clostridial neurotoxins","volume":"54","author":"Brunger","year":"2009","journal-title":"Toxicon"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1471-4159.2009.06093.x","article-title":"Cell entry strategy of clostridial neurotoxins","volume":"109","author":"Binz","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.toxicon.2008.11.018","article-title":"Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel","volume":"54","author":"Montal","year":"2009","journal-title":"Toxicon"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1371\/journal.ppat.0030113","article-title":"Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain","volume":"3","author":"Brunger","year":"2007","journal-title":"PLoS Pathog."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29604","DOI":"10.1074\/jbc.M703619200","article-title":"Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes","volume":"282","author":"Fischer","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1073\/pnas.0400229101","article-title":"Plasma membrane localization signals in the light chain of botulinum neurotoxin","volume":"101","author":"Steward","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16554","DOI":"10.1073\/pnas.1008302107","article-title":"Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system","volume":"107","author":"Tsai","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1074\/jbc.M111.224493","article-title":"Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25","volume":"286","author":"Chen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.chembiol.2007.03.014","article-title":"Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility","volume":"14","author":"Silvaggi","year":"2007","journal-title":"Chem. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/bi052518r","article-title":"Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: Repercussions for VAMP-2 substrate specificity","volume":"45","author":"Arndt","year":"2006","journal-title":"Biochemistry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.1021\/bi0510072","article-title":"Structural analysis of botulinum neurotoxin serotype F light chain: Implications on substrate binding and inhibitor design","volume":"44","author":"Agarwal","year":"2005","journal-title":"Biochemistry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9574","DOI":"10.1021\/bi0505924","article-title":"Crystal structure of botulinum neurotoxin type G light chain: Serotype divergence in substrate recognition","volume":"44","author":"Arndt","year":"2005","journal-title":"Biochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8291","DOI":"10.1021\/bi050253a","article-title":"Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme","volume":"44","author":"Agarwal","year":"2005","journal-title":"Biochemistry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1021\/bi701162d","article-title":"Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: Implications for dual substrate specificity","volume":"46","author":"Jin","year":"2007","journal-title":"Biochemistry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1471-4159.1999.0720327.x","article-title":"Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage","volume":"72","author":"Vaidyanathan","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0021-9258(17)42071-0","article-title":"Proteolysis of SNAP-25 by types E and A botulinal neurotoxins","volume":"269","author":"Binz","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1021\/bi00255a017","article-title":"Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments","volume":"33","author":"Foran","year":"1994","journal-title":"Biochemistry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nature03123","article-title":"Substrate recognition strategy for botulinum neurotoxin serotype A","volume":"432","author":"Breidenbach","year":"2004","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nsmb.1626","article-title":"Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F","volume":"16","author":"Agarwal","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1074\/jbc.M611211200","article-title":"Mechanism of substrate recognition by botulinum neurotoxin serotype A","volume":"282","author":"Chen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_44","first-page":"219","article-title":"Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins","volume":"19","author":"Atassi","year":"1999","journal-title":"Crit. Rev. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1054\/jocn.2000.0684","article-title":"The current use of botulinum toxin","volume":"7","author":"Mahant","year":"2000","journal-title":"J. Clin. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1097\/00002508-200211001-00012","article-title":"Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes","volume":"18","author":"Glogau","year":"2002","journal-title":"Clin. J. Pain"},{"key":"ref_47","first-page":"RA40","article-title":"Emerging therapeutic applications of botulinum toxin","volume":"9","author":"Thant","year":"2003","journal-title":"Med. Sci. Monit."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1047-9651(03)00064-0","article-title":"Use of botulinum toxin type A and type B for spasticity in upper and lower limbs","volume":"14","author":"Bell","year":"2003","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.anplas.2004.09.002","article-title":"Botulinum toxin and wrinkles: Few side effects and effective combining procedures with other treatments","volume":"49","author":"Ascher","year":"2004","journal-title":"Ann. Chir. Plast. Esthet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clindermatol.2004.04.001","article-title":"Commentary: Botulinum toxin in clinical medicine: Part II","volume":"22","author":"Benedetto","year":"2004","journal-title":"Clin. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2146\/sp\/06001","article-title":"Unlabeled uses of botulinum toxins: A review, part 2","volume":"63","author":"Cheng","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajog.2006.03.108","article-title":"Botulinum toxin: From life-threatening disease to novel medical therapy","volume":"196","author":"Mahajan","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1517\/13543784.10.12.2191","article-title":"Botulinum toxin type B: A new injectable treatment for cervical dystonia","volume":"10","author":"Brashear","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"(2001). Neurotoxins Licensed as Treatment for Neck Neuromuscular Disorder. Am. J. Health Syst. Pharm., 58:200.","DOI":"10.1093\/ajhp\/58.3.200"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003495-200262040-00011","article-title":"Botulinum toxin B: A review of its therapeutic potential in the management of cervical dystonia","volume":"62","author":"Figgitt","year":"2002","journal-title":"Drugs"},{"key":"ref_57","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus","volume":"79","author":"Scott","year":"1981","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3928\/0191-3913-19800101-06","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"17","author":"Scott","year":"1980","journal-title":"J. Pediatric Ophthalmol. Strabismus"},{"key":"ref_59","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles","volume":"12","author":"Scott","year":"1973","journal-title":"Investig. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/09638280701568189","article-title":"Botulinum toxin in the treatment of strabismus. A review of its use and effects","volume":"29","author":"Kowal","year":"2007","journal-title":"Disabil. Rehabil."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00347-007-1573-2","article-title":"Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?","volume":"104","author":"Krzizok","year":"2007","journal-title":"Ophthalmologe"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Rowe, F.J., and Noonan, C.P. (2009). Botulinum toxin for the treatment of strabismus. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD006499.pub2"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Rowe, F.J., and Noonan, C.P. (2011). Botulinum toxin for the treatment of strabismus. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD006499.pub3"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"64. Hancox, J.; Sharma, S.; Mackenzie, K.; Adams, G. The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismus. Br. J. Ophthalmol. 2012, doi: 10.1136\/bjophthalmol-2011-301332.","DOI":"10.1136\/bjophthalmol-2011-301332"},{"key":"ref_65","first-page":"1","article-title":"Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm (In Chinese)","volume":"62","author":"Chang","year":"1999","journal-title":"Chin. Med. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0008-4182(01)80084-3","article-title":"Botulinum toxin for blepharospasm and hemifacial spasm: Stability of duration of effect and dosage over time","volume":"36","author":"Drummond","year":"2001","journal-title":"Can. J. Ophthalmol."},{"key":"ref_67","first-page":"61","article-title":"Treatment of hemifacial spasm with botulinum A toxin","volume":"32","author":"Duzynski","year":"1998","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_68","first-page":"41","article-title":"Hemifacial spasm and its treatment with botulinum toxin","volume":"77","author":"Turki","year":"1999","journal-title":"Tunis. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Costa, J., Espirito-Santo, C., Borges, A., Ferreira, J.J., Coelho, M., Moore, P., and Sampaio, C. (2004). Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004899"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"ref_71","first-page":"267","article-title":"Botulinum toxin A-Injection for cervical dystonia","volume":"47","author":"Bhaumik","year":"1999","journal-title":"J. Assoc. Physicians India"},{"key":"ref_72","first-page":"109","article-title":"Cervical dystonia: A review the role of botulinum toxin","volume":"80","author":"Edwards","year":"1995","journal-title":"Nebr. Med. J."},{"key":"ref_73","first-page":"179","article-title":"Use of botulinum toxin in the treatment of cervical dystonia","volume":"2","author":"Poewe","year":"1993","journal-title":"Baillieres Clin. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"ref_75","first-page":"473","article-title":"Botulinum toxin in cervical dystonia","volume":"49","author":"Tsui","year":"1988","journal-title":"Adv. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","article-title":"Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia","volume":"20","author":"Factor","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Costa, J., Espirito-Santo, C., Borges, A., Ferreira, J.J., Coelho, M., Moore, P., and Sampaio, C. (2004). Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004315.pub2"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Costa, J., Borges, A., Espirito-Santo, C., Ferreira, J., Coelho, M., Moore, P., and Sampaio, C. (2004). Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004315.pub2"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D30WC8C21S","article-title":"What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A","volume":"15","author":"Benohanian","year":"2009","journal-title":"Dermatol. Online J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2133.2007.07760.x","article-title":"Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: A randomized, side-by-side, double-blind study","volume":"156","author":"Simonart","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-Week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.urology.2005.08.016","article-title":"Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions","volume":"67","author":"Kuo","year":"2006","journal-title":"Urology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","article-title":"Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections","volume":"53","author":"Game","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum Toxin A Versus Placebo for Refractory Detrusor Overactivity in Women: A Randomised Blinded Placebo-Controlled Trial of 240 Women (the RELAX Study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","article-title":"Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: Clinical and urodynamic results","volume":"55","author":"Giannantoni","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11916-007-0217-1","article-title":"Treatment of chronic low back pain with botulinum neurotoxins","volume":"11","author":"Jabbari","year":"2007","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.ajp.0000174267.06993.3f","article-title":"Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: A prospective trial of 60 patients","volume":"22","author":"Ney","year":"2006","journal-title":"Clin. J. Pain"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00002508-200307000-00011","article-title":"Use of botulinum toxin in the treatment of chronic myofascial pain","volume":"19","author":"Valia","year":"2003","journal-title":"Clin. J. Pain"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1097\/00002508-200211001-00007","article-title":"A focused review of the use of botulinum toxins for low back pain","volume":"18","author":"Difazio","year":"2002","journal-title":"Clin. J. Pain"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1212\/WNL.56.10.1290","article-title":"Botulinum toxin A and chronic low back pain: A randomized, double-blind study","volume":"56","author":"Foster","year":"2001","journal-title":"Neurology"},{"key":"ref_97","first-page":"283","article-title":"Botulinum toxin and gastrointestinal tract disorders: Panacea, placebo, or pathway to the future?","volume":"4","author":"Lacy","year":"2008","journal-title":"Gastroentero. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF03033934","article-title":"Botulinum toxin for gastrointestinal disorders: Therapy and mechanisms","volume":"9","author":"Vittal","year":"2006","journal-title":"Neurotox Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2298\/VSP0405531S","article-title":"Botulinum toxin A in the treatment of anal fissure","volume":"61","author":"Stankovic","year":"2004","journal-title":"Vojnosanit Pregl."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00004836-200202000-00004","article-title":"Gastrointestinal uses of botulinum toxin","volume":"34","author":"Qureshi","year":"2002","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/bega.1999.0013","article-title":"Botulinum toxin for spastic gastrointestinal disorders","volume":"13","author":"Hoogerwerf","year":"1999","journal-title":"Baillieres Best Pract Res. Clin. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0022-3468(97)90650-3","article-title":"Botulinum toxin use in pediatric esophageal achalasia: A case report","volume":"32","author":"Walton","year":"1997","journal-title":"J. Pediatr. Surg."},{"key":"ref_103","first-page":"929","article-title":"Gastrointestinal uses of botulinum toxin","volume":"92","author":"Bhutani","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00415-010-5526-3","article-title":"Botulinum toxin type A in post-stroke lower limb spasticity: A multicenter, double-blind, placebo-controlled trial","volume":"257","author":"Kaji","year":"2010","journal-title":"J. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1586\/ern.09.121","article-title":"Botulinum toxin type A for upper limb spasticity after stroke","volume":"9","author":"Shaw","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"ref_106","first-page":"22","article-title":"Botulinum toxin in spasticity treatment in adults","volume":"79","author":"Ward","year":"2008","journal-title":"Nervenarzt"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/PHM.0b013e318168ceaf","article-title":"The use of botulinum toxin for spasticity after spinal cord injury","volume":"87","author":"Marciniak","year":"2008","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_108","first-page":"19","article-title":"Treatment of juvenile spasticity with botulinum toxin type A","volume":"79","author":"Desloovere","year":"2008","journal-title":"Nervenarzt"},{"key":"ref_109","first-page":"65","article-title":"Botulinum toxin: A new dimension for spasticity","volume":"149","author":"Reichel","year":"2007","journal-title":"MMW Fortschr. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00002018-200629010-00003","article-title":"Botulinum toxin treatment of adult spasticity : A benefit-risk assessment","volume":"29","author":"Sheean","year":"2006","journal-title":"Drug Saf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0269215506cr931oa","article-title":"Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): A systematic Cochrane review","volume":"20","author":"Watts","year":"2006","journal-title":"Clin. Rehabil."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00702-007-0757-x","article-title":"Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs","volume":"115","author":"Watts","year":"2008","journal-title":"J. Neural Transm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1469-8749.1987.tb08830.x","article-title":"Drooling and its management in cerebral palsy","volume":"29","author":"Harris","year":"1987","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mds.10276","article-title":"Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study","volume":"17","author":"Hyson","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_115","first-page":"289","article-title":"Efficacy and safety of botulinum toxin in the treatment of sialorrhea in children with neurological disorders","volume":"77","author":"Miranda","year":"2012","journal-title":"An. Pediatr. (Barc)"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0032-1307457","article-title":"Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: A focus on effectiveness and therapy adherence","volume":"43","author":"Schroeder","year":"2012","journal-title":"Neuropediatrics"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: A prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0278-2391(99)90007-1","article-title":"The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings","volume":"57","author":"Freund","year":"1999","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00702-007-0864-8","article-title":"Evidence based medicine in the use of botulinum toxin for back pain","volume":"115","author":"Jabbari","year":"2008","journal-title":"J. Neural. Transm."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10787-010-0069-x","article-title":"The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: A systematic review and meta analysis","volume":"19","author":"Zhang","year":"2011","journal-title":"Inflammopharmacology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/AOG.0b013e3181bb0dbb","article-title":"Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome","volume":"114","author":"Bertolasi","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/j.1743-6109.2011.02247.x","article-title":"Different treatment modalities for refractory vaginismus in western Saudi Arabia","volume":"8","author":"Fageeh","year":"2011","journal-title":"J. Sex. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s10350-005-0179-5","article-title":"Improvement of wound healing after hemorrhoidectomy: A double-blind, randomized study of botulinum toxin injection","volume":"48","author":"Patti","year":"2005","journal-title":"Dis. Colon Rectum"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.4065\/81.8.1023","article-title":"Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study","volume":"81","author":"Gassner","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1097\/01.prs.0000209944.45949.d1","article-title":"Use of botulinum toxin type A to prevent widening of facial scars","volume":"117","author":"Wilson","year":"2006","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_127","first-page":"50","article-title":"Effect of botulinum toxin type A on the expression of substance P, calcitonin gene-related peptide, transforming growth factor beta-1 and alpha smooth muscle actin A in wound healing in rats","volume":"25","author":"Wang","year":"2009","journal-title":"Chin. Plast. Surg."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.urology.2008.07.051","article-title":"Botulinum toxin-A to improve urethral wound healing: An experimental study in a rat model","volume":"73","author":"Sahinkanat","year":"2009","journal-title":"Urology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/molecules17022169","article-title":"Effects of botulinum toxin type a on collagen deposition in hypertrophic scars","volume":"17","author":"Xiao","year":"2012","journal-title":"Molecules"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1097\/00002508-200211001-00010","article-title":"A focused review on the use of botulinum toxins for neuropathic pain","volume":"18","author":"Argoff","year":"2002","journal-title":"Clin. J. Pain"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.2337\/dc05-2486","article-title":"Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy","volume":"29","author":"Restivo","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00063-008-1075-2","article-title":"New therapeutic approaches to diabetic gastroparesis","volume":"103","author":"Hummel","year":"2008","journal-title":"Med. Klin (Munich)"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","article-title":"Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial","volume":"72","author":"Yuan","year":"2009","journal-title":"Neurology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.01.020","article-title":"Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection","volume":"633","author":"Lackovic","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_135","first-page":"2200","article-title":"Successful treatment of diabetic gustatory hyperhidrosis with topical glycopyrrolate","volume":"173","author":"Lund","year":"2011","journal-title":"Ugeskr Laeger"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrm2002","article-title":"SNAREs-Engines for membrane fusion","volume":"7","author":"Jahn","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"33023","DOI":"10.1074\/jbc.272.52.33023","article-title":"SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion","volume":"272","author":"Sadoul","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.4049\/jimmunol.164.11.5850","article-title":"Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: Functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment","volume":"164","author":"Paumet","year":"2000","journal-title":"J. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1006\/bbrc.2000.2525","article-title":"Quantification of SNARE protein levels in 3T3-L1 adipocytes: Implications for insulin-stimulated glucose transport","volume":"270","author":"Hickson","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood.V95.3.921.003k17_921_929","article-title":"Molecular mechanisms of platelet exocytosis: Role of SNAP-23 and syntaxin 2 in dense core granule release","volume":"95","author":"Chen","year":"2000","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V96.7.2574","article-title":"Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis","volume":"96","author":"Nabokina","year":"2000","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0161-5890(02)00084-6","article-title":"Function of the t-SNARE SNAP-23 and secretory carrier membrane proteins (SCAMPs) in exocytosis in mast cells","volume":"38","author":"Castle","year":"2002","journal-title":"Mol. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0960-9822(03)00006-X","article-title":"The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion","volume":"13","author":"Pagan","year":"2003","journal-title":"Curr. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.4049\/jimmunol.175.10.6686","article-title":"Identification of soluble N-ethylmaleimide-sensitive factor attachment protein receptor exocytotic machinery in human plasma cells: SNAP-23 is essential for antibody secretion","volume":"175","author":"Reales","year":"2005","journal-title":"J. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbrc.2006.03.093","article-title":"Epithelial sodium channel is regulated by SNAP-23\/syntaxin 1A interplay","volume":"343","author":"Saxena","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03354881","article-title":"Re-engineering the target specificity of Clostridial neurotoxins-A route to novel therapeutics","volume":"9","author":"Foster","year":"2006","journal-title":"Neurotox Res."},{"key":"ref_147","first-page":"1134","article-title":"Physiology of airway mucus secretion and pathophysiology of hypersecretion","volume":"52","author":"Rogers","year":"2007","journal-title":"Respir. Care"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev.physiol.70.113006.100638","article-title":"Regulated airway goblet cell mucin secretion","volume":"70","author":"Davis","year":"2008","journal-title":"Annu. Rev. Physiol"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-Therapeutic consequences","volume":"147","author":"Goschel","year":"1997","journal-title":"Exp. Neurol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1081\/IMM-120016244","article-title":"Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response","volume":"31","author":"Dolimbek","year":"2002","journal-title":"Immunol. Invest."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/B:JOPC.0000016257.91979.06","article-title":"Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A","volume":"23","author":"Atassi","year":"2004","journal-title":"Protein J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1002\/mds.20024","article-title":"Treatment of cervical dystonia with botulinum toxin","volume":"19","author":"Jankovic","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03033933","article-title":"Botulinum toxin therapy for cervical dystonia","volume":"9","author":"Jankovic","year":"2006","journal-title":"Neurotox. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"ref_157","unstructured":"Brin, M.F., Hallett, M., and Jankovic, J. (2002). Scientific and Therapeutic Aspects of Botulinum Toxin, Lippincott Willams & Wilkins."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0733-8619(08)80005-9","article-title":"Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia","volume":"26","author":"Swope","year":"2008","journal-title":"Neurol. Clin."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-007-0831-4","article-title":"The treatment of cervical dystonia with botulinum toxins","volume":"115","author":"Comella","year":"2008","journal-title":"J. Neural. Transm."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08977190009003240","article-title":"A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro","volume":"18","author":"Chaddock","year":"2000","journal-title":"Growth Factors"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/IAI.68.5.2587-2593.2000","article-title":"Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A","volume":"68","author":"Chaddock","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"34846","DOI":"10.1074\/jbc.M202902200","article-title":"Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin","volume":"277","author":"Duggan","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.20008","article-title":"Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain","volume":"19","author":"Chaddock","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1359-6446(05)03389-1","article-title":"A new wrinkle on pain relief: Re-engineering clostridial neurotoxins for analgesics","volume":"10","author":"Foster","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1073\/pnas.0903111106","article-title":"Engineering botulinum neurotoxin to extend therapeutic intervention","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.toxicon.2009.01.037","article-title":"Engineered toxins: New therapeutics","volume":"54","author":"Foster","year":"2009","journal-title":"Toxicon"},{"key":"ref_167","unstructured":"Rummel, A. (2004). Transport Protein which is used to Introduce Chemical Compounds into Nerve Cells. (2006\/027207), International patent application WO."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1021\/bi3000098","article-title":"Insights into the Different Catalytic Activities of Clostridium Neurotoxins","volume":"51","author":"Chen","year":"2012","journal-title":"Biochemistry"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10930-007-9118-8","article-title":"Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity","volume":"27","author":"Ahmed","year":"2008","journal-title":"Protein J."},{"key":"ref_170","unstructured":"Chen, S. (Unpublished work, 2012). Unpublished work."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molimm.2006.03.011","article-title":"Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT\/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT\/A","volume":"44","author":"Dolimbek","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.molimm.2008.06.031","article-title":"Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment","volume":"45","author":"Atassi","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imbio.2011.08.009","article-title":"Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT\/B molecule","volume":"217","author":"Atassi","year":"2012","journal-title":"Immunobiology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1073\/pnas.89.13.5852","article-title":"Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide","volume":"89","author":"Atassi","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2011.02.002","article-title":"Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates","volume":"137","author":"Dolimbek","year":"2011","journal-title":"Immunol. Lett."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/mds.20006","article-title":"Is the light chain subcellular localization an important factor in botulinum toxin duration of action?","volume":"19","author":"Ho","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1074\/jbc.M110.181784","article-title":"A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: Transfer of longevity to a novel potential therapeutic","volume":"286","author":"Wang","year":"2011","journal-title":"J. Biol. Chem."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/4\/10\/913\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:52:59Z","timestamp":1760219579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/4\/10\/913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,19]]},"references-count":177,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10]]}},"alternative-id":["toxins4100913"],"URL":"https:\/\/doi.org\/10.3390\/toxins4100913","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,19]]}}}